NCT05258279

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Mutations

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Juntendo University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations.

Conditions

• Non-squamous Non-small-cell Lung Cancer
• EGFR Activating Mutation

Interventions

Type	Name	Description
DRUG	Pembrolizumab	IV infusion Q3W
DRUG	Lenvatinib	Oral capsule once daily
DRUG	Carboplatin	IV infusion Q3W
DRUG	Pemetrexed	IV infusion Q3W

Timeline

• Start date: 2022-07-01
• Primary completion: 2023-10-31
• Completion: 2024-10-01
• First posted: 2022-02-28
• Last updated: 2024-08-28

Locations

10 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study